SARS-CoV-2 RapidPlex: a graphene-based multiplexed telemedicine platform for rapid and low-cost COVID-19 diagnosis and monitoring
Loading...
Download
Official URL
Full text at PDC
Publication date
2020
Advisors (or tutors)
Editors
Journal Title
Journal ISSN
Volume Title
Publisher
Elsevier
Citations
Exportar
Citation
Rebeca M. Torrente-Rodríguez, Heather Lukas, Jiaobing Tu, Jihong Min, Yiran Yang, Changhao Xu, Harry B. Rossiter, Wei Gao, SARS-CoV-2 RapidPlex: A Graphene-Based Multiplexed Telemedicine Platform for Rapid and Low-Cost COVID-19 Diagnosis and Monitoring, Matter, Volume 3, Issue 6, 2020, Pages 1981-1998, ISSN 2590-2385, https://doi.org/10.1016/j.matt.2020.09.027.
Abstract
The COVID-19 pandemic is an ongoing global challenge for public health systems. Ultrasensitive and early identification of infection is critical in preventing widespread COVID-19 infection by presymptomatic and asymptomatic individuals, especially in the community and in-home settings. We demonstrate a multiplexed, portable, wireless electrochemical platform for ultra-rapid detection of COVID-19: the SARS-CoV-2 RapidPlex. It detects viral antigen nucleocapsid protein, IgM and IgG antibodies, as well as the inflammatory biomarker C-reactive protein, based on our mass-producible laserengraved graphene electrodes. We demonstrate ultrasensitive, highly selective, and rapid electrochemical detection in the physiologically relevant ranges. We successfully evaluated the applicability of our SARS-CoV-2 RapidPlex platform with COVID19-positive and COVID-19-negative blood and saliva samples. Based on this pilot study, our multiplexed immunosensor platform may allow for high-frequency at-home testing for COVID-19 telemedicine diagnosis and monitoring.
Description
The need for widespread testing to control the spread of COVID-19 has faced challenges due to testing backlogs, limited access to required equipment, and inaccurate assay results. To address this, we propose an ultrasensitive and low-cost telemedicine platform, the SARSCoV-2 RapidPlex, based on target-specific immunoassays built off laser-engraved graphene for rapid and remote assessment of COVID-19 biomarkers (i.e., nucleocapsid protein, anti-spike protein IgG and IgM, and Creactive protein). Multiplex sensing of these targets provides information on three key aspects of COVID-19 disease: viral infection, immune response, and disease severity. We successfully demonstrated the platform’s applicability using COVID-19- positive and COVID-19-negative serum and saliva samples. The SARS-CoV-2 RapidPlex has the potential to quickly and effectively triage patients and track infection progression, allowing for the clear identification of individuals who are infectious, vulnerable, and/or immune.